Novartis ($NVS) held about half its market share as India's Sun Pharmaceuticals launched a generic version of blood cancer drug Gleevec/Glivec (imatinib) in the U.S. at the start of February--but that figure is expected to collapse by the third quarter as the 180-day market exclusivity ends and a swarm of new offers appear.